NASDAQ:CRISCuris Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.84 -0.01 (-1.18 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$0.80Now: $0.84▼$0.8550-Day Range$0.63MA: $0.80▼$0.9952-Week Range$0.62Now: $0.84▼$2.90Volume62,429 shsAverage Volume161,253 shsMarket Capitalization$30.55 millionP/E RatioN/ADividend YieldN/ABeta2.38 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Curis. Previous Next 2.6 Community Rank Outperform VotesCuris has received 651 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCuris has received 588 “underperform” votes. (Add your “underperform” vote.)Community SentimentCuris has received 52.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote “Outperform” if you believe CRIS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRIS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCuris does not currently pay a dividend.Dividend GrowthCuris does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Curis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.60% of the stock of Curis is held by insiders.Percentage Held by InstitutionsOnly 22.06% of the stock of Curis is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Curis is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Curis is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CRIS Previous Symbol CUSIP23126910 CIK1108205 Webwww.curis.com Phone617-503-6500Debt Debt-to-Equity RatioN/A Current Ratio2.76 Quick Ratio2.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10 million Price / Sales3.06 Cash FlowN/A Price / Cash FlowN/A Book Value($1.10) per share Price / Book-0.76Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-32,140,000.00 Net Margins-292.04% Return on EquityN/A Return on Assets-83.96%Miscellaneous Employees55 Outstanding Shares36,580,000Market Cap$30.55 million Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:CRIS Rates by TradingView Receive CRIS News and Ratings via Email Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Curis (NASDAQ:CRIS) Frequently Asked Questions How has Curis' stock been impacted by COVID-19 (Coronavirus)? Curis' stock was trading at $1.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRIS stock has decreased by 23.4% and is now trading at $0.8352. View which stocks have been most impacted by Coronavirus. When is Curis' next earnings date? Curis is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Curis. How were Curis' earnings last quarter? Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings results on Tuesday, May, 12th. The biotechnology company reported ($0.28) earnings per share for the quarter. The biotechnology company had revenue of $2.71 million for the quarter. During the same quarter in the prior year, the business posted ($0.33) EPS. View Curis' earnings history. When did Curis' stock split? How did Curis' stock split work? Curis shares reverse split before market open on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split. Has Curis been receiving favorable news coverage? News stories about CRIS stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Curis earned a news impact score of 2.8 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutCuris. Are investors shorting Curis? Curis saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 59,900 shares, a decrease of 12.4% from the April 30th total of 68,400 shares. Based on an average trading volume of 193,800 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the shares of the stock are sold short. View Curis' Current Options Chain. Who are some of Curis' key competitors? Some companies that are related to Curis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors. What other stocks do shareholders of Curis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Novavax (NVAX), Celldex Therapeutics (CLDX), Micron Technology (MU), Crispr Therapeutics (CRSP), CTI BioPharma (CTIC), Inovio Pharmaceuticals (INO), Zynga (ZNGA), Agenus (AGEN) and Geron (GERN). Who are Curis' key executives? Curis' management team includes the following people: Mr. James E. Dentzer, Pres, CEO & Director (Age 52)Dr. Robert E. Martell, Head of R&D (Age 56)Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 60)Mr. Bill Steinkrauss, Corp. Controller & Sr. Director of Fin.Mr. Daniel R. Passeri M.Sc., MSc., J.D., Consultant (Age 58) What is Curis' stock symbol? Curis trades on the NASDAQ under the ticker symbol "CRIS." Who are Curis' major shareholders? Curis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Arnhold LLC (1.96%). Company insiders that own Curis stock include James E Dentzer, Kenneth I Kaitin and Robert Martell. View institutional ownership trends for Curis. Which major investors are buying Curis stock? CRIS stock was purchased by a variety of institutional investors in the last quarter, including Arnhold LLC. View insider buying and selling activity for Curis. How do I buy shares of Curis? Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Curis' stock price today? One share of CRIS stock can currently be purchased for approximately $0.84. How big of a company is Curis? Curis has a market capitalization of $30.55 million and generates $10 million in revenue each year. Curis employs 55 workers across the globe. What is Curis' official website? The official website for Curis is www.curis.com. How can I contact Curis? Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected] This page was last updated on 5/31/2020 by MarketBeat.com Staff
